Trial Profile
A Phase II, Open Label, Two-Arm Study of Therapeutic Iobenguane (131I) as Single Agent or in Combination With Vorinostat for Recurrent or Progressive High- Risk Neuroblastoma Subjects (OPTIMUM TRIAL)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Feb 2023
Price :
$35
*
At a glance
- Drugs Iobenguane (Primary) ; Vorinostat (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- Acronyms OPTIMUM
- Sponsors Jubilant DraxImage
- 15 Feb 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
- 22 Nov 2021 Planned primary completion date changed from 1 Apr 2023 to 1 Dec 2022.
- 26 May 2021 Planned number of patients changed from 65 to 60.